ACADIA Pharmaceuticals Inc (NAS:ACAD)
$ 16.95 -0.42 (-2.42%) Market Cap: 2.89 Bil Enterprise Value: 2.37 Bil PE Ratio: 22.27 PB Ratio: 5.01 GF Score: 75/100

ACADIA Pharmaceuticals Inc at Stifel Virtual Healthcare Conference Transcript

Nov 17, 2020 / 08:20PM GMT
Release Date Price: $55.29 (+1.21%)
Paul Andrew Matteis
Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst

Great. Thanks, everyone, for joining. Happy to be hosting this panel with Steve Davis, CEO of ACADIA Pharmaceuticals; and Elena Ridloff, Chief Financial Officer. We're going to keep it mostly conversational, but Steve, I think you wanted to make some prepared remarks and give a more high level update, and then we can get into Q&A. So thank you, again, and please take it away.

Stephen R. Davis
ACADIA Pharmaceuticals Inc. - CEO & Director

Great. Thanks much, Paul. Yes, just to level set a little bit before we get started with the Q&A. And by the way, very much appreciate being able to present at your conference today. I do need to start with just a brief reminder that the business of pharmaceutical development and commercialization has certain inherent risks. So please see a copy of our most recent SEC filings for a description of how these risks relate to our business.

I'd like to briefly highlight our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot